Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041835 | 0.97 | ALDH1A1 (0.37) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL15208490 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL11686332 | 0.82 | ALDH1A1 (0.32) | TSHRALDH1A1FFAR3LCKFYN | |
| SCHEMBL3035945 | 0.78 | — | — | |
| SCHEMBL2552626 | 0.76 | HDAC6 (0.35) | — | |
| SCHEMBL2517858 | 0.76 | TSHR (0.35) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL15312738 | 0.74 | — | — | |
| SCHEMBL5394152 | 0.74 | — | — | |
| SCHEMBL286191 | 0.74 | LMNA (0.32) | — | |
| SCHEMBL345565 | 0.73 | TSHR (0.42) | TSHRALDH1A1CYP2D6CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3990455-A1 | PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264081-A1 | PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3271368-B1 | NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2018-10-31 | — | — | EP | disclosed |
| EP-3271368-A1 | NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017121969-A1 | NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2017-07-20 | — | — | WO | disclosed |
| EP-3119796-A1 | SYNTHESIS OF BICYCLIC NUCLEOSIDES | Miragen Therapeutics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015142735-A1 | SYNTHESIS OF BICYCLIC NUCLEOSIDES | MiRagen Therapeutics, Inc. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-9028785-B2 | High CO2 to amine adsorption capacity CO2 scrubbing processes | EXXONMOBIL RESEACH AND ENGINEERING COMPANY (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2614042-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | Evonik Degussa GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | disclosed |
| WO-2003103599-A2 | CASPASE-1 INHIBITORS AND METHODS FOR THEIR USE | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | disclosed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | TSHR 3132/4885ALDH1A1 263/4885HMGCR 2459/4885 |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | TSHR 2894/4885ALDH1A1 434/4885HMGCR 2593/4885 |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | TSHR 2894/4885ALDH1A1 434/4885HMGCR 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.